Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070486 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT00070486 is a Phase 2 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 140 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00070486, a Phase 2 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib and zileuton may stop the growth of tumor cells by stopping blood flow to the tumor and may block the enzymes necessary for tumor cell growth. Combining chemotherapy with celecoxib and/or zileuton may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combining celecoxib and/or zileuton with carboplatin and gemcitabine in treating patients who have advanced non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG gemcitabine hydrochloride
- DRUG celecoxib
- DRUG zileuton
Study Locations (20)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center - Los Angeles
- Naval Medical Center - San Diego - San Diego
- Veterans Affairs Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- CCOP - Evanston - Evanston
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Cancer Center at Memorial Regional Hospital - Hollywood
- CCOP - Mount Sinai Medical Center - Miami Beach
- Palm Beach Cancer Institute - West Palm Beach
District of Columbia
- Lombardi Cancer Center at Georgetown University Medical Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Delaware
- CCOP - Christiana Care Health Services - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2003-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070486
The ClinicalTrials.gov registry entry for NCT00070486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00070486 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00070486 about?
NCT00070486 is a clinical study titled "Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib and zileuton may stop the growth of tumor cells by stopping blood flow to the tumor and may block the enzymes necessary for tumo...
What is the current status of trial NCT00070486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2003-12. Estimated completion is 2011-05.
What conditions does trial NCT00070486 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00070486?
The interventions under investigation include: carboplatin (DRUG), gemcitabine hydrochloride (DRUG), celecoxib (DRUG), zileuton (DRUG).
Who is sponsoring clinical trial NCT00070486?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070486 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.